Frank H. Laukien Ph.D.
Net Worth
Last updated:
What is Frank H. Laukien Ph.D. net worth?
The estimated net worth of Dr. Frank H. Laukien Ph.D. is at least $1,440,836,499 as of 18 Nov 2024. He owns shares worth $1,309,761,529 as insider, has earned $106,924,970 from insider trading and has received compensation worth at least $24,150,000 in Bruker Corporation.
What is the salary of Frank H. Laukien Ph.D.?
Dr. Frank H. Laukien Ph.D. salary is $1,150,000 per year as Chairman, Chief Executive Officer & Pres in Bruker Corporation.
How old is Frank H. Laukien Ph.D.?
Dr. Frank H. Laukien Ph.D. is 65 years old, born in 1960.
What stocks does Frank H. Laukien Ph.D. currently own?
As insider, Dr. Frank H. Laukien Ph.D. owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Bruker Corporation (BRKR) | Chairman, Chief Executive Officer & Pres | 38,409,429 | $34.1 | $1,309,761,529 |
What does Bruker Corporation do?
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Frank H. Laukien Ph.D. insider trading
Bruker Corporation
Dr. Frank H. Laukien Ph.D. has made 28 insider trades between 2004-2024, according to the Form 4 filled with the SEC. Most recently he purchased 26,551 units of BRKR stock worth $1,349,322 on 18 Nov 2024.
The largest trade he's ever made was exercising 1,000,000 units of BRKR stock on 15 Jun 2015. As of 18 Nov 2024 he still owns at least 38,409,429 units of BRKR stock.
Bruker key executives
Bruker Corporation executives and other stock owners filed with the SEC:
- Dr. Falko Busse Ph.D. (58) Pres of Bruker BioSpin Group
- Dr. Frank H. Laukien Ph.D. (65) Chairman, Chief Executive Officer & Pres
- Dr. Mark R. Munch Ph.D. (63) Executive Vice President and Pres of Bruker Nano Group & Bruker Nano Surfaces Division
- Mr. Gerald N. Herman (67) Executive Vice President, Chief Financial Officer, Corporation Controller & Interim Head of IR
- Mr. Juergen Srega (70) Pres of Bruker CALID Group & Bruker Daltonics Division